AUROBINDO

February 21, 2020

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25th Floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804

Dear Sir,

Sub: Further update on US FDA Inspection at our Unit IV – Reg.,

Ref : 1. Our letter dated 13th November 2019
2. Our letter dated 19th February 2020

Further to our intimations dated November 13, 2019 and February 19, 2020 with regard to the USFDA inspection of Unit IV, a general injectable formulation manufacturing facility of the Company, and issue of Establishment Inspection Report (EIR) with Voluntary Action Initiated (VAI) status by USFDA, we hereby inform the following:

Today, February 21, 2020, the Company received a communication that the inspection conducted by the U.S. Food and Drug Administration (USFDA) at our aforesaid Unit IV, from November 4, 2019 to November 13, 2019, is still open and under review, by way of rescindment of 90-day VAI letter that was issued by them on February 18, 2020.

Please note that the communication of February 18, 2020 (which was already intimated) and February 21, 2020 as received by us from US FDA now, is being communicated to the Stock Exchanges.

Please take the above information on record.

Thanking you,

Yours faithfully,
For **AUROBINDO PHARMA LIMITED**

B. Adi Reddy
Company Secretary

AUROBINDO PHARMA LTD. * HYD. *